Palliative embolization for osteosarcoma

被引:22
作者
Mavrogenis A.F. [1 ]
Rossi G. [2 ]
Rimondi E. [3 ]
Calabrò T. [4 ]
Papagelopoulos P.J. [1 ]
Ruggieri P. [4 ]
机构
[1] First Department of Orthopaedics, Athens University Medical School, 41 Ventouri Street, Holargos, Athens
[2] Department of Interventional Angiographic Radiology, Istituto Ortopedico Rizzoli, Bologna
[3] Department of Radiology, Istituto Ortopedico Rizzoli, Bologna
[4] Department of Orthopaedics, Istituto Ortopedico Rizzoli, Bologna
关键词
Embolization; Osteosarcoma; Palliative;
D O I
10.1007/s00590-013-1312-0
中图分类号
学科分类号
摘要
Background: The prognosis of patients with metastatic, recurrent, and/or unresectable osteosarcoma is poor. Aggressive local and medical treatments are available for palliation. Palliative treatments include isolated limb perfusion, radiation therapy, embolization, chemoembolization, thermal ablation, and cryoablation. Their aim is pain relief and tumor size reduction with minimum complications.; Materials and methods: We present 19 patients with metastatic, recurrent, and/or unresectable osteosarcoma of the pelvis and lower lumbar spine treated with palliative selective embolization using N-2-butyl cyanoacrylate. All patients had chemotherapy. At the time of embolization, they experienced severe pain refractory to analgesics. Diagnostic angiography was performed pre-embolization to determine the vascular mapping and hemodynamic status of the tumor. Post-embolization angiography was done to evaluate for complete occlusion of the pathological vessels. Mean follow-up was 18 months. Local pain, tumor necrosis and size, and complications were recorded.; Conclusion: Selective arterial embolization is a useful local palliative treatment for patients with advanced osteosarcoma for pain relief.; Results: In all patients, pre-embolization angiography showed hypervascularity of the tumor from extensive neovascularization. Five patients had repeat embolization. All patients experienced pain relief at a mean of 3 days post-embolization. No patient had recurrent pain with the intensity of that before embolization. Variable tumor necrosis was observed in follow-up imaging, and reduction in tumor size was minimum. All patients experienced pain at the site of embolization, which resolved completely 1–5 days after embolization. Four patients with pelvic osteosarcomas experienced paraesthesias at the distribution of the sciatic nerve. © 2013, Springer-Verlag France.
引用
收藏
页码:1351 / 1356
页数:5
相关论文
共 35 条
[1]  
Wittig J.C., Bickels J., Priebat D., Jelinek J., Kellar-Graney K., Shmookler B., Malawer M.M., Osteosarcoma: a multidisciplinary approach to diagnosis and treatment, Am Fam Physician, 65, 6, pp. 1123-1132, (2002)
[2]  
Bacci G., Ferrari S., Mercuri M., Longhi A., Capanna R., Tienghi A., Brach del Prever A., Comandone A., Cesari M., Bernini G., Picci P., Neoadjuvant chemotherapy for extremity osteosarcoma–preliminary results of the Rizzoli’s 4th study, Acta Oncol, 37, 1, pp. 41-48, (1998)
[3]  
Longhi A., Errani C., De Paolis M., Mercuri M., Bacci G., Primary bone osteosarcoma in the pediatric age: state of the art, Cancer Treat Rev, 32, 6, pp. 423-436, (2006)
[4]  
Errani C., Longhi A., Rossi G., Rimondi E., Biazzo A., Toscano A., Ali N., Ruggieri P., Alberghini M., Picci P., Bacci G., Mercuri M., Palliative therapy for osteosarcoma, Expert Rev Anticancer Ther, 11, 2, pp. 217-227, (2011)
[5]  
Bacci G., Briccoli A., Longhi A., Ferrari S., Mercuri M., Faggioli F., Versari M., Picci P., Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy, Acta Oncol, 44, 7, pp. 748-755, (2005)
[6]  
Jaffe N., Bruland O.S., Bielack S.S., Pediatric and adolescent osteosarcoma, (2009)
[7]  
Kempf-Bielack B., Bielack S.S., Jurgens H., Branscheid D., Berdel W.E., Exner G.U., Gobel U., Helmke K., Jundt G., Kabisch H., Kevric M., Klingebiel T., Kotz R., Maas R., Schwarz R., Semik M., Treuner J., Zoubek A., Winkler K., Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS), J Clin Oncol, 23, 3, pp. 559-568, (2005)
[8]  
Grignani G., Palmerini E., Dileo P., Asaftei S.D., D'Ambrosio L., Pignochino Y., Mercuri M., Picci P., Fagioli F., Casali P.G., Ferrari S., Aglietta M., A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study, Ann Oncol [Epub ahead of print], (2011)
[9]  
Merimsky O., Kollender Y., Inbar M., Meller I., Bickels J., Palliative treatment for advanced or metastatic osteosarcoma, Isr Med Assoc J, 6, 1, pp. 34-38, (2004)
[10]  
Malawer M.M., Link M.P., Donaldson S.S., Sarcomas of bone, Cancer: principles and practice of oncology, pp. 1731-1752, (1997)